Catalent completes acquisition of R P Scherer Eberbach
Buys remaining 49% of firm from Gelita
Catalent Pharma Solutions, a global drug delivery technology company based in Somerset, NJ in the US, has completed its purchase of the remaining 49% of R P Scherer Eberbach, Germany from gelatine specialist Gelita.
Financial terms were not revealed.
After 60 years of joint partnership, Catalent and Gelita have agreed that the R P Scherer Eberbach business will be better able to serve the growing European pharmaceutical and consumer health softgel market with R P Scherer fully integrated into Catalent. Under full Catalent ownership, customers will have access to a wider range of drug development and delivery technologies/services, and a global supply chain network.
Gelita will continue to provide the R P Scherer plant, located on its premises at Eberbach, with gelatin, energy, steam, and fresh water.
R P Scherer Corporation (including the Eberbach joint venture) was founded by Robert Pauli Scherer’s patented rotary die production process for softgel capsules and was sold to Cardinal Health PTS, which is now Catalent Pharma Solutions. Catalent and R P Scherer Eberbach have a long heritage of experience and recognised expertise in softgel formulation and operations.
‘We are proud of the strong Catalent and R P Scherer Eberbach legacy and are very excited about the future of softgel innovation as an important part of the development, delivery and market supply of pharmaceutical and nutraceutical products,’ said David Heyens, president of Catalent’s Softgel Business.
‘This acquisition comes on the heels of ongoing investment that Catalent is making in its softgel facilities in Buenos Aires, Argentina; Aprilia, Italy; and St Petersburg, Florida; and other investments in advanced drug delivery technologies in Germany and the US.’
